OncoMatch/Clinical Trials/NCT06483347
Checkpoint Inhibitor Combinations Therapy as First Line for Inoperable Lung Cancer Via IT
Is NCT06483347 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies ipilimumab+pembrolizumab or ipilimumab+durvalumab, idarubicin, bevacizumab for lung cancer.
Treatment: ipilimumab+pembrolizumab or ipilimumab+durvalumab, idarubicin, bevacizumab — This trial is designed to investigate the safety, response rates and survival outcomes of patients with inoperable lung cancer by infusion of CTLA4, PD1 and PDL1 antibodies combination with chemodrug or/and bevacizumab through intra-tumor (IT).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Cancer type
Non-Small Cell Lung Carcinoma
Small Cell Lung Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: clinical trial therapy (equipment or drugs)
Patients participated in clinical trials of equipment or drugs (signed informed consent) within 4 weeks
Lab requirements
Blood counts
WBC ≥ 3.0×10E9/L; Hb ≥ 90g/L; PLT ≥ 50×10E9/L; INR < 2.3 or PT < 6 seconds above control; Impaired clotting test (platelet count < 60000/mm3, prothrombin activity < 50%) [excluded]
Kidney function
Cr ≤ 145.5 umul/L; Renal failure / insufficiency requiring hemo-or peritoneal dialysis [excluded]
Liver function
Child-Pugh class A or B/Child score > 7; Albumin > 28 g/L; Total bilirubin < 51 μmol/L
Cardiac function
No serious heart disease; Known severe atheromatosis [excluded]; Known uncontrolled blood hypertension (> 160/100 mm/Hg) [excluded]
Child-Pugh class A or B/Child score > 7; WBC ≥ 3.0×10E9/L; Hb ≥ 90g/L; PLT ≥ 50×10E9/L; INR < 2.3 or PT < 6 seconds above control; Cr ≤ 145.5 umul/L; Albumin > 28 g/L; Total bilirubin < 51 μmol/L; Impaired clotting test (platelet count < 60000/mm3, prothrombin activity < 50%) [excluded]; Renal failure / insufficiency requiring hemo-or peritoneal dialysis [excluded]; Known severe atheromatosis [excluded]; Known uncontrolled blood hypertension (> 160/100 mm/Hg) [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06483347 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior clinical trial therapy (equipment or drugs) disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify